Principal Investigators

    DERREUMAUX Philippert


    LBT Paris

    Contact information of lead PI



    Title of project or programme

    A new Generation of Drugs for ALzheimer’s disease based on in vitro and in silico experiments of beta-amyloid oligomers and in vivo tests

    Source of funding information


    Total sum awarded (Euro)

    € 584,927

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Alzheimer's disease & other dementias


    Research Abstract

    GRAL: Generation of efficient drugs against Alzheimer’s disease
    Alzheimer’s disease is affecting more than 24 million people worlwide and represents a 1000 billion dollars cost to our society. Thus far, no disease-modifying treatments exist.
    A scientific challenge: determination of the first 3D structures of the amyloid-beta protein complexed by inhibitors to discover efficient drugs
    The GRAL project, which integrates different and complementary expertises from chemistry, biophysics, structural biology, computer simulations, in silico design and screening of compounds to transgenic flies and mice, aims at discovering efficient therapeitic agents against Alzheimer’s disease.
    State of the art in vitro, in silico and in vivo methods
    Low-resolution experimental methods used: DLS, SEC, AUC, TEM, ESI-MI, Spectroscopies (CD, FTIR, Fluorescence).
    Insights into atomic information from NMR, and spin labels followed by EPR.
    Multi-scale computer simulations (all-atom, coarse grained OPEP)
    Discovery of very efficient drugs validated by tests on transgenic flies and mice.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: France
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF